Is Supernus Pharmaceuticals (SUPN) overvalued or fairly valued?

MarketChacha shows Supernus Pharmaceuticals's valuation in context — a forward P/E of about 9.9, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Supernus Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (9.02×) from reported figures — education, not a rating.

What is Supernus Pharmaceuticals's revenue?

Supernus Pharmaceuticals reported revenue of $719.0M for FY2025, with net profit of $-38.5M, per official filings.

What is the share price of Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals last traded at $43.95 (-0.0% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Supernus Pharmaceuticals

SUPN · NYSE · Healthcare · United States

Snapshot

TickerSUPN

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees778

HeadquartersRockville, United States

Websitewww.supernus.com

Filings tracked25

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Who owns it

Insiders4.3%
Institutions95.7%
Public & other0.0%

459 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.09%
Millennium Management Llc6.63%
Vanguard Portfolio Management LLC5.69%
Armistice Capital, LLC4.55%
Vanguard Capital Management LLC4.33%
State Street Corporation4.23%
Nomura Asset Management International Inc4.09%
Dimensional Fund Advisors LP3.58%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Cash conversion9.02×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend0.2% → -5.4%

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Return on equity-3.6%

Latest ROE of -3.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $238.3M · EPS 1.08

Est. earnings growth +23.0%

Next fiscal year

Rev $1.4B · EPS 4.46

Est. earnings growth +73.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$719.0M

Net margin

-5.4%

ROE

-3.6%

Revenue CAGR (2y)

+8.8%

EPS (FY2025)

-0.68

Net profit (FY2025)

$-38.5M

Ask MarketChacha about SUPN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$719.0M	$-38.5M	-0.68	-5.4%	-3.6%
FY2024	$661.8M	$73.9M	1.32	11.2%	7.1%
FY2023	$607.5M	$1.3M	0.02	0.2%	0.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$219.1M	$-58.4M	-1.01	-26.6%
2026Q1	$207.7M	$-2.3M	-0.04	-1.1%
2025Q3	$192.1M	$-45.1M	-0.80	-23.5%
2025Q2	$165.5M	$22.5M	0.40	13.6%
2025Q1	$149.8M	$-11.8M	-0.21	-7.9%
2024Q3	$175.7M	$38.5M	0.69	21.9%
2024Q2	$168.3M	$19.9M	0.36	11.8%
2024Q1	$143.6M	$124,000	0.00	0.1%
2023Q3	$153.9M	$-16.0M	-0.29	-10.4%
2023Q2	$135.6M	$-831,000	-0.02	-0.6%
2023Q1	$153.8M	$16.9M	0.29	11.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events, Exhibits
SEC8/3/2026material
8-K — Material agreement, Executive/director change, Other events, Exhibits
SEC8/3/2026material
8-K — Results of operations, Exhibits
SEC8/3/2026material
10-Q filing
SEC8/3/2026
8-K — Other events, Exhibits
SEC8/3/2026material
8-K — Results of operations, Exhibits
SEC7/22/2026material
8-K — Shareholder vote results, Exhibits
SEC6/18/2026material
8-K — Material financial obligation, Exhibits
SEC5/20/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations
SEC4/22/2026material
8-K — Material agreement, Completion of acquisition/disposition, Exhibits
SEC4/7/2026material
10-K filing
SEC3/2/2026
8-K — Results of operations, Exhibits
SEC2/24/2026material
8-K — Executive/director change, Exhibits
SEC2/24/2026material
8-K — Results of operations, Exhibits
SEC2/12/2026material
8-K — Exhibits
SEC1/28/2026material

2025

10-Q filing
SEC11/6/2025
8-K — Results of operations, Reg FD disclosure
SEC11/4/2025material
8-K — Results of operations, Exhibits
SEC10/21/2025material
8-K/A — Exhibits
SEC10/16/2025
8-K — Results of operations
SEC8/5/2025material
10-Q filing
SEC8/5/2025
8-K — Executive/director change
SEC8/4/2025material
8-K — Material agreement, Completion of acquisition/disposition, Other events, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.